486422-31-5

Basic information

• Product Name: 1-[(4-Bromobenzene)sulfonyl]-4-methylhomopiperazine
• Synonyms: 1-[(4-Bromobenzene)sulfonyl]-4-methylhomopiperazine;1-(4-bromophenyl)sulfonyl-4-methyl-1,4-diazepane
• CAS NO: 486422-31-5
• Molecular Formula: C₁₂H₁₇BrN₂O₂S
• Molecular Weight: 333
• Mol File: 486422-31-5.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 417.2±55.0 °C(Predicted)
• Appearance: /
• Density: 1.450±0.06 g/cm3(Predicted)
• PKA: 7.54±0.10(Predicted)
• CAS DataBase Reference: 1-[(4-Bromobenzene)sulfonyl]-4-methylhomopiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(4-Bromobenzene)sulfonyl]-4-methylhomopiperazine(486422-31-5)
• EPA Substance Registry System: 1-[(4-Bromobenzene)sulfonyl]-4-methylhomopiperazine(486422-31-5)

Safety Data

• Hazardous Substances Data: 486422-31-5(Hazardous Substances Data)

Usage

Type of compound

Sulfonyl derivative of 4-methylhomopiperazine

Bromobenzene group

Present in the compound

Usage

Building block in the synthesis of pharmaceuticals and other organic compounds

Physical state

White to off-white solid

Solubility

Sparingly soluble in water, soluble in organic solvents

Importance

Versatile and important intermediate in organic chemistry

Upstream product

• 4318-37-0 1-Methylhomopiperazine 
• 98-58-8 4-bromobenzenesulfonyl chloride 

Relevant articles and documents

Protozoan Parasite Growth Inhibitors Discovered by Cross-Screening Yield Potent Scaffolds for Lead Discovery

Tropical protozoal infections are a significant cause of morbidity and mortality worldwide; four in particular (human African trypanosomiasis (HAT), Chagas disease, cutaneous leishmaniasis, and malaria) have an estimated combined burden of over 87 million disability-adjusted life years. New drugs are needed for each of these diseases. Building on the previous identification of NEU-617 (1) as a potent and nontoxic inhibitor of proliferation for the HAT pathogen (Trypanosoma brucei), we have now tested this class of analogs against other protozoal species: T. cruzi (Chagas disease), Leishmania major (cutaneous leishmaniasis), and Plasmodium falciparum (malaria). Based on hits identified in this screening campaign, we describe the preparation of several replacements for the quinazoline scaffold and report these inhibitors' biological activities against these parasites. In doing this, we have identified several potent proliferation inhibitors for each pathogen, such as 4-((3-chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)-6-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)quinoline-3-carbonitrile (NEU-924, 83) for T. cruzi and N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-7-(4-((4-methyl-1,4-diazepan-1-yl)sulfonyl)phenyl)cinnolin-4-amine (NEU-1017, 68) for L. major and P. falciparum.

SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C

This invention relates to 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid(benzyl-cyano-methyl)-amides of formula 1 and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.

IMIDAZOLYL-SUBSTITUTED AZABENZOPHENONE COMPOUNDS

The compounds of formula (I) in which X, Y, R1 and R2 have the meanings as given in the description are novel effective inhibitors of the inducible nitric oxide synthase.